JP2017506623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506623A5 JP2017506623A5 JP2016549334A JP2016549334A JP2017506623A5 JP 2017506623 A5 JP2017506623 A5 JP 2017506623A5 JP 2016549334 A JP2016549334 A JP 2016549334A JP 2016549334 A JP2016549334 A JP 2016549334A JP 2017506623 A5 JP2017506623 A5 JP 2017506623A5
- Authority
- JP
- Japan
- Prior art keywords
- bag3
- vector
- expression
- bcl2
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 claims description 110
- 101710089791 BAG family molecular chaperone regulator 3 Proteins 0.000 claims description 110
- 238000000034 method Methods 0.000 claims description 59
- 239000013598 vector Substances 0.000 claims description 56
- 239000013604 expression vector Substances 0.000 claims description 40
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 35
- 108091012583 BCL2 Proteins 0.000 claims description 35
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 238000003556 assay Methods 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 18
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 239000013603 viral vector Substances 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 9
- 208000019622 heart disease Diseases 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 241000702421 Dependoparvovirus Species 0.000 claims description 7
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 210000005003 heart tissue Anatomy 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 239000002071 nanotube Substances 0.000 claims description 6
- 241000709687 Coxsackievirus Species 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 241000125945 Protoparvovirus Species 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 150000002484 inorganic compounds Chemical class 0.000 claims description 5
- 229910010272 inorganic material Inorganic materials 0.000 claims description 5
- 229930014626 natural product Natural products 0.000 claims description 5
- 150000002894 organic compounds Chemical class 0.000 claims description 5
- 239000000816 peptidomimetic Substances 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 238000000018 DNA microarray Methods 0.000 claims description 4
- 238000004166 bioassay Methods 0.000 claims description 4
- 238000000423 cell based assay Methods 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000001952 enzyme assay Methods 0.000 claims description 4
- 238000012188 high-throughput screening assay Methods 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 238000002493 microarray Methods 0.000 claims description 4
- 238000002823 phage display Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 238000003566 phosphorylation assay Methods 0.000 claims description 3
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 2
- 238000012801 analytical assay Methods 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 238000013537 high throughput screening Methods 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- -1 porous strips Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 8
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000007482 whole exome sequencing Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102100039181 Ankyrin repeat domain-containing protein 1 Human genes 0.000 description 1
- 101150039216 Bag3 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100033324 GATA zinc finger domain-containing protein 1 Human genes 0.000 description 1
- 101000889396 Homo sapiens Ankyrin repeat domain-containing protein 1 Proteins 0.000 description 1
- 101000926786 Homo sapiens GATA zinc finger domain-containing protein 1 Proteins 0.000 description 1
- 101000982003 Homo sapiens Myopalladin Proteins 0.000 description 1
- 101001062129 Homo sapiens RNA-binding protein 20 Proteins 0.000 description 1
- 101000645320 Homo sapiens Titin Proteins 0.000 description 1
- 101150035410 IKZF5 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100026786 Myopalladin Human genes 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 102100029248 RNA-binding protein 20 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100026260 Titin Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934483P | 2014-01-31 | 2014-01-31 | |
| US61/934,483 | 2014-01-31 | ||
| PCT/US2015/013926 WO2015117010A2 (en) | 2014-01-31 | 2015-01-30 | Bag3 as a target for therapy of heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019191740A Division JP7079761B2 (ja) | 2014-01-31 | 2019-10-21 | 心不全の治療のための標的としてのｂａｇ３ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506623A JP2017506623A (ja) | 2017-03-09 |
| JP2017506623A5 true JP2017506623A5 (enExample) | 2018-05-24 |
| JP6920818B2 JP6920818B2 (ja) | 2021-08-18 |
Family
ID=53757927
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549334A Active JP6920818B2 (ja) | 2014-01-31 | 2015-01-30 | 心不全の治療のための標的としてのｂａｇ３ |
| JP2019191740A Active JP7079761B2 (ja) | 2014-01-31 | 2019-10-21 | 心不全の治療のための標的としてのｂａｇ３ |
| JP2022083707A Active JP7558218B2 (ja) | 2014-01-31 | 2022-05-23 | 心不全の治療のための標的としてのｂａｇ３ |
| JP2024160090A Pending JP2024175055A (ja) | 2014-01-31 | 2024-09-17 | 心不全の治療のための標的としてのｂａｇ３ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019191740A Active JP7079761B2 (ja) | 2014-01-31 | 2019-10-21 | 心不全の治療のための標的としてのｂａｇ３ |
| JP2022083707A Active JP7558218B2 (ja) | 2014-01-31 | 2022-05-23 | 心不全の治療のための標的としてのｂａｇ３ |
| JP2024160090A Pending JP2024175055A (ja) | 2014-01-31 | 2024-09-17 | 心不全の治療のための標的としてのｂａｇ３ |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11236389B2 (enExample) |
| EP (2) | EP3099333B8 (enExample) |
| JP (4) | JP6920818B2 (enExample) |
| CA (2) | CA3228845A1 (enExample) |
| DK (1) | DK3099333T3 (enExample) |
| ES (1) | ES2838804T3 (enExample) |
| HU (1) | HUE052814T2 (enExample) |
| PT (1) | PT3099333T (enExample) |
| SI (1) | SI3099333T1 (enExample) |
| WO (1) | WO2015117010A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3099333B8 (en) * | 2014-01-31 | 2020-12-30 | Temple University of the Commonwealth System of Higher Education | Bag3 as a target for therapy of heart failure |
| EP3337518A4 (en) * | 2015-08-17 | 2019-06-12 | Temple University Of The Commonwealth System Of Higher Education | BAG3 COMPOSITIONS AND METHOD |
| CN105769900A (zh) * | 2016-03-22 | 2016-07-20 | 山西大学 | Bag3基因在制备抗膀胱癌药物中的应用 |
| KR101804678B1 (ko) | 2016-05-30 | 2017-12-04 | 가톨릭대학교 산학협력단 | Bis 억제제 스크리닝용 마커, 이를 포함하는 스크리닝 키트 및 이를 이용한 bis 억제제 스크리닝 방법 |
| IT201600069391A1 (it) * | 2016-07-04 | 2016-10-04 | Univ Degli Studi Di Salerno | Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare |
| MX2019001729A (es) * | 2016-08-11 | 2019-11-12 | Univ Temple | Lesion por isquemia/reperfusion. |
| WO2018129528A1 (en) * | 2017-01-09 | 2018-07-12 | Duke University | Methods for treating ischemic injury |
| EP3658582A1 (en) | 2017-07-28 | 2020-06-03 | Intrepida Bio, Inc. | Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases |
| IT201700113648A1 (it) * | 2017-10-10 | 2019-04-10 | Biouniversa Srl | Anti-BAG3 antibodies as therapeutic reagent in cardiovascular diseases |
| BR112020016666A2 (pt) * | 2018-02-15 | 2020-12-15 | Tomas Björklund | Capsídeos virais modificados |
| MX2020013334A (es) * | 2018-06-08 | 2021-05-27 | Univ Temple | Optimización de terapia génica de bag3. |
| KR20210089718A (ko) * | 2018-11-08 | 2021-07-16 | 유니버시티 오브 마이애미 | 확장성 심근병증에서 세포 요법에 대한 반응성을 결정하는 방법 |
| US20220088127A1 (en) * | 2019-01-15 | 2022-03-24 | Temple University - Of The Commonwealth System Of Higher Education | Targeting the bag family for the treatment of neurodegenerative disease |
| WO2020205889A1 (en) | 2019-04-01 | 2020-10-08 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
| MX2024001939A (es) * | 2021-08-12 | 2024-07-10 | Univ Temple | Administracion retrograda de composicion terapeutica mediante seno o vena coronarios. |
| CA3235431A1 (en) * | 2021-10-22 | 2023-04-27 | Arthur M. Feldman | Bag3 methods and uses for treatment of inflammation |
| US20250041453A1 (en) * | 2021-12-10 | 2025-02-06 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector |
| WO2023147558A2 (en) * | 2022-01-28 | 2023-08-03 | Temple University - Of The Commonwealth System Of Higher Education | Crispr methods for correcting bag3 gene mutations in vivo |
| CN119072323A (zh) * | 2022-04-22 | 2024-12-03 | 航天七号有限责任公司 | 使用aav载体的b细胞淋巴瘤2关联永生基因3(bag3)基因疗法 |
| CN119255814A (zh) * | 2022-05-03 | 2025-01-03 | 联邦高等教育系统天普大学 | 脑中bag3和蛋白质的质量控制 |
| CA3267841A1 (en) * | 2022-09-16 | 2024-03-21 | Temple University Of The Commonwealth System Of Higher Education | METHODS AND USES OF BAG3 FOR THE TREATMENT OF CARDIAC AMYLOIDOSIS |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| EP0260032B1 (en) | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1989005358A1 (en) | 1987-11-30 | 1989-06-15 | University Of Iowa Research Foundation | Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
| US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
| US4907603A (en) | 1988-01-04 | 1990-03-13 | Bertha D. Chambers | Safety smoke |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
| US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5605662A (en) | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
| US5670113A (en) | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
| US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| WO1995015972A1 (en) | 1993-12-09 | 1995-06-15 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
| JPH10501681A (ja) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | 核酸送達システムならびにその合成および使用方法 |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
| KR101014207B1 (ko) | 2001-11-13 | 2011-02-14 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 아데노-결합 바이러스 (ａａｖ) 서열을 검출 및/또는 확인하는 방법 및 그 방법에 의해 확인된 신규한 서열을 분리하는 방법 |
| EP1323733A1 (en) | 2001-12-28 | 2003-07-02 | Arturo Leone | BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases |
| US20030175958A1 (en) * | 2002-03-15 | 2003-09-18 | Reed John C. | Methods for using bag expression as a cell differentiation agent and marker |
| WO2009105135A1 (en) | 2008-02-19 | 2009-08-27 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
| WO2010138263A2 (en) * | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| WO2012087835A2 (en) * | 2010-12-22 | 2012-06-28 | Boston Biomedical Research Institute | Compositions and methods for enhancing protein folding |
| WO2012107580A1 (en) | 2011-02-10 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | In vitro diagnosis method for predicting a predisposition to cardiomyopathy |
| EP3099333B8 (en) | 2014-01-31 | 2020-12-30 | Temple University of the Commonwealth System of Higher Education | Bag3 as a target for therapy of heart failure |
| MX2024001939A (es) | 2021-08-12 | 2024-07-10 | Univ Temple | Administracion retrograda de composicion terapeutica mediante seno o vena coronarios. |
-
2015
- 2015-01-30 EP EP15743948.0A patent/EP3099333B8/en active Active
- 2015-01-30 ES ES15743948T patent/ES2838804T3/es active Active
- 2015-01-30 DK DK15743948.0T patent/DK3099333T3/da active
- 2015-01-30 WO PCT/US2015/013926 patent/WO2015117010A2/en not_active Ceased
- 2015-01-30 HU HUE15743948A patent/HUE052814T2/hu unknown
- 2015-01-30 JP JP2016549334A patent/JP6920818B2/ja active Active
- 2015-01-30 PT PT157439480T patent/PT3099333T/pt unknown
- 2015-01-30 CA CA3228845A patent/CA3228845A1/en active Pending
- 2015-01-30 CA CA2975258A patent/CA2975258A1/en active Pending
- 2015-01-30 US US15/115,807 patent/US11236389B2/en active Active
- 2015-01-30 EP EP20208165.9A patent/EP3812473A1/en active Pending
- 2015-01-30 SI SI201531453T patent/SI3099333T1/sl unknown
-
2019
- 2019-10-21 JP JP2019191740A patent/JP7079761B2/ja active Active
-
2020
- 2020-05-21 US US15/929,784 patent/US11542555B2/en active Active
-
2022
- 2022-05-23 JP JP2022083707A patent/JP7558218B2/ja active Active
- 2022-10-05 US US17/938,209 patent/US20230073246A1/en active Pending
-
2024
- 2024-09-17 JP JP2024160090A patent/JP2024175055A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506623A5 (enExample) | ||
| DK2299275T3 (en) | Classification of oncofetal fetronectin level for pregnancy-related indications | |
| RU2730836C2 (ru) | Вычислительный анализ биологических данных с применением многообразия и гиперплоскости | |
| CN109661578B (zh) | 用于区分细菌和病毒感染的蛋白质特征 | |
| US7659243B2 (en) | Treatment of ALS and variants thereof consisting of primary lateral sclerosis (PLS) or spinal muscular atrophy (SMA) | |
| JP2022028790A (ja) | 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物 | |
| EP1354199A2 (en) | Diagnosis and treatment of multiple sclerosis | |
| JP2013511732A (ja) | 神経障害の診断、診断補助および／またはその進行のモニタリングのための方法、キットおよび試薬 | |
| CN112920275B (zh) | 可特异性结合sST2的结合蛋白、试剂和试剂盒 | |
| CN116322750A (zh) | 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法 | |
| CN115703837B (zh) | 一种抗生长刺激表达基因2蛋白的重组抗体 | |
| JP2010539891A (ja) | 心臓血管及び血栓性の危険性の決定のためのｃｌｅｃ１ｂの使用 | |
| JP2009506301A (ja) | Ｐｉｆファミリーの新たなタンパク質アイソフォーム及びその使用 | |
| JP2007523640A5 (enExample) | ||
| TW201643191A (zh) | 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一） | |
| CN112940130A (zh) | 能够特异性结合mpo的结合蛋白、其用途、试剂、试剂盒和检测mpo的方法 | |
| CN110320367A (zh) | 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用 | |
| WO2001063293A2 (en) | Diagnosis and treatment of schizophrenia | |
| CN104650214B (zh) | 肺动脉高压致病基因acvrl1突变位点及其应用 | |
| KR20230174589A (ko) | 비타민 관련 바이오 복합체에 특이적으로 결합하는 펩타이드 및 이의 용도 | |
| RU2000119129A (ru) | Молекула днк, кодирующая мутантный препронейропептид y, мутантный сигнальный пептид и их применения | |
| CN117434270B (zh) | 一种可携带放射性信号的蛋白质支架及其抗体检测中的应用 | |
| TW201643192A (zh) | 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（二） | |
| KR102476905B1 (ko) | 허혈성 질환 진단 또는 예후 진단용 바이오마커 | |
| CN114085900B (zh) | 与遗传性肾小球疾病相关的突变基因及其应用 |